الصفحة الرئيسية>>Signaling Pathways>> Immunology/Inflammation>> Aryl Hydrocarbon Receptor>>CAY10465

CAY10465

رقم الكتالوجGC18824

CAY10465 هو ناهض AhR انتقائي وعالي التقارب ، مع Ki يبلغ 0.2 نانومتر ، ولا يظهر أي تأثير على مستقبلات هرمون الاستروجين (Ki\u003e 100000 نانومتر).

Products are for research use only. Not for human use. We do not sell to patients.

CAY10465 التركيب الكيميائي

Cas No.: 688348-33-6

الحجم السعر المخزون الكميّة
1mg
21٫00
متوفر
5mg
74٫00
متوفر
10mg
130٫00
متوفر
50mg
502٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CAY 10465 is a selective and high-affinity AhR agonist, with a Ki of 0.2 nM, and shows no effect on estrogen receptor (Ki >100000 nM).

CAY 10465 (Compound 4i) is a selective and high-affinity AhR receptor agonist, with a Ki of 0.2 nM, and shows no effect on estrogen receptor (Ki >100000 nM)[1]. CAY 10465 (0.01 nM-100 μM) reduces apolipoprotein A-I (apo A-I) levels in HepG2 cells, and inhibits the synthesis of the protein[2].

References:
[1]. de Medina P, et al. Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators. J Med Chem. 2005 Jan 13;48(1):287-91.
[2]. Naem E, et al. Inhibition of apolipoprotein A-I gene by the aryl hydrocarbon receptor: a potential mechanism for smoking-associated hypoalphalipoproteinemia. Life Sci. 2012 Jul 26;91(1-2):64-9.

مراجعات

Review for CAY10465

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CAY10465

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.